Latest News
Jul 15, 2021
Lytix Biopharma initiates the Phase II combination study in the US with LTX-315 and Pembrolizumab in patients with solid tumors
May 31, 2021
Lytix Biopharma AS: Contemplated private placement and listing on Euronext Growth Oslo
May 25, 2021
Lytix Biopharma strengthens the board of directors with nominating Marie-Louise Fjällskog, Evelina Vågesjö, Kjetil Hestdal and Jayson Rieger as new directors